To test this idea, we asked if gene correction could limit TP53 mutational prevalence in FA tissue when TP53 mutation rates and proliferative advantages were comparable for FANC– and FANC+ cells (Fig 4C and 4F). Here, TP53 is linked to Friedreich ataxia.